New delivery systems potential for current anti-allergy drugs

Present drug delivery systems such as oral administration and intravenous injection limit the drug efficacy of current anti-allergy drugs. Therefore, new drug delivery systems, including nanocarriers, transdermal patches, and microneedles, are being investigated for their potential to deliver anti-allergy drugs. The review reveals the likely improvements by applying new drug delivery systems, including nanocarriers, transdermal patches and microneedles. These new drug delivery systems utilize local administration and do not undergo metabolism pathways in the liver. Thus, they demonstrate high drug targeting, rapid onset action, precise dosage control, and minimal side effects. Limitations on large-scale production and high costs hinder the application of advanced drug delivery systems. Fortunately, forthcoming innovation and maturation will likely overcome the barriers and enable general patients to access anti-allergy drugs delivered by these advanced drug delivery systems, resulting in optimal body functions for everyday life. Despite their limitations, new drug delivery systems are still promising solutions for delivering anti-allergy drugs due to their enhanced drug concentration, shortened onset time, and reduced systemic side effects.